ACRV — Acrivon Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1781174 ·
Last close
$1.43
Market Cap
$61.28M
52W High
$3.56
52W Low
$1.27
ADV30
220,277
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -18,518,000 -17,897,000 85,748,000 47,535,000 14,974,000
Jun 2026 0 — -18,668,000 -17,964,000 99,092,000 41,417,000 12,427,000
Mar 2026 0 — -19,902,000 -19,042,000 107,832,000 34,064,000 12,317,000
Dec 2025 0 — -20,116,000 -18,985,000 129,717,000 41,499,000 17,201,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-62,920,000
Investing CF
$55,509,000
Financing CF
$6,927,000
CapEx
$-1,219,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.94
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-311,887,000
Inventory
—
Receivables
—
ST Investments
$48,542,000
EBIT TTM
$-78,373,000
Pretax Income TTM
$-74,225,000
Interest Exp TTM
—
Analysts
6

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -84,114,000 -77,905,000 129,717,000 17,201,000 112,516,000 -63,665,000
Dec 2024 0 -89,199,000 -80,556,000 196,588,000 19,802,000 176,786,000 -65,669,000
Dec 2023 0 -67,103,000 -60,388,000 138,265,000 17,070,000 121,195,000 -42,641,000
Dec 2022 0 -32,657,000 -31,167,000 181,226,000 10,751,000 170,475,000 -30,117,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-74,225,000
OpCashFlow TTM
—
Assets (Latest)
$99,092,000
Forward EPS
$-1.69

Peers — same industry

TickerNameMarket CapLastDaily %
FBIO Fortress Biotech, Inc. $60.70M $1.82 —
KZIA KAZIA THERAPEUTICS LTD $60.68M $5.31 —
LFVN Lifevantage Corp $60.62M $4.78 —
CRBP Corbus Pharmaceuticals Holdings, Inc. $62.03M $3.01 —
RANI Rani Therapeutics Holdings, Inc. $64.61M $0.56 —

News headlines (Yahoo Finance, 1h cache)

Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
2026-11-06 13:00 · Yahoo
Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
2026-11-04 21:30 · Yahoo
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR S
2026-10-29 12:00 · Yahoo
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
2026-10-20 12:30 · Yahoo
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
2026-09-15 16:00 · Yahoo
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
2026-09-03 13:55 · Yahoo
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
2026-09-02 12:00 · Yahoo
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
2026-08-31 12:30 · Yahoo
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
2026-08-24 16:00 · Yahoo
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
2026-07-21 20:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.